What Should Be Known by a Urologist About the Medical Management of COVID-19's Patients?

PURPOSE OF REVIEW: The alarming number of confirmed COVID-19 cases put a strain on the healthcare systems, which had to reallocate human and technical resources to respond to the emergency. Many urologists became integrated into multidisciplinary teams, dealing with this respiratory illness and its unknown management. It aims to summarize the epidemiological, clinical, diagnostical, and therapeutical characteristics of COVID-19, from a practical perspective, to ease COVID-19 management to non-physician staff. RECENT FINDINGS: We performed a narrative review of the literature regarding COVID-19, updated to May 8th, 2020, at PubMed and COVID resource platforms of the main scientific editorials. COVID-19, characterized by fever, myalgias, dyspnea, and dry cough, varies widely from asymptomatic infection to death. Arrhythmias and thrombotic events are prevalent. Lymphopenia and inflammatory reactant elevation on laboratory, as well as bilateral and peripheral ground-glass opacities or consolidations on X-Ray, are usually found in its assessment. Little is known about SARS-CoV-2 immunology. To date, no therapy has demonstrated efficacy in COVID-19. Of-level or compassionate-use therapies are prescribed in the context of clinical trials. We should become familiar with specific adverse events and pharmacological interactions. The COVID-19 pandemic has paralyzed the urological activity, and its long-term consequences are unpredictable. Despite not being used to deal with respiratory diseases, the urologists become easily qualified to manage COVID-19 by following protocols and being integrated into multidisciplinary teams, helping to overcome the pandemic.

Castleman's disease presented as a retroperitoneal mass.

OBJECTIVE: We report one case of Castleman's disease and review published literature. METHODS: We report the case of a 58 year old man who was referred to our institution because of lumbar pain. A computed tomography scan revealed a retroperitoneal mass. Open surgical exploration and excision were carried out. Finally pathological examination addressed the diagnosis. RESULTS: Pathological examination demonstrated findings characteristic of unicentric hyaline vascular type of Castleman's disease. After surgical excision and 12 months follow-up there is no evidence of recurrence disease. CONCLUSIONS: Castleman's disease is a rare lymphoproliferative disorder of uncertain etiology. Retroperitoneal localization is exceptional.

Enfermedad de Castleman de localización retroperitoneal: A propósito de un caso / Castleman´s disease presented as a retroperitoneal mass

OBJETIVO: Presentamos el caso de una enfermedad de Castleman de localización retroperitoneal y revisamos la literatura. MÉTODO: Se presenta el caso de un paciente de 58 años de edad que fue remitido a nuestro centro por dolor lumbar. La tomografía axial computerizada demostró una masa retroperitoneal. Se decide entonces llevar a cabo una exploración quirúrgica y exéresis de la misma. Finalmente el estudio histológico determinó el diagnóstico. RESULTADOS: El estudio histológico fue congruente hiperplasia angiofolicular (enfermedad de Castleman) unicéntrica tipo hialino-vascular. Tras tratamiento quirúrgico radical el paciente evolucionó de forma satisfactoria encontrándose libre de recurrencia a los 12 meses. CONCLUSIONES: La enfermedad de Castleman es un proceso linfoproliferativo poco frecuente y de etiología desconocida. La localización retroperitoneal es excepcional (AU)

OBJECTIVE: We report one case of Castleman’s disease and review published literature. METHODS: We report the case of a 58 year old man who was referred to our institution because of lumbar pain. A computed tomography scan revealed a retroperitoneal mass. Open surgical exploration and excision were carried out. Finally pathological examination addressed the diagnosis. RESULTS: Pathological examination demonstrated findings characteristic of unicentric hyaline vascular type of Castleman’s disease. After surgical excision and 12 months follow-up there is no evidence of recurrence disease. CONCLUSIONS: Castleman’s disease is a rare lymphoproliferative disorder of uncertain etiology. Retroperitoneal localization is exceptional (AU)